HAMARI Holdings Inc.
Basic information
- Head office
- 1-19-40 Minamikita, Suminoe-ku, Osaka City, Osaka Prefecture 559-0034
- Chief executive
- Kei Takami
- Capital
- 11,000,000 JPY
- Employees (non-consolidated)
- Employees (consolidated)
- 401 people
- Start date
- 2023-01-20
- End date
Websites
Business
Related companies
| Company name | Group | Parent | Subsidiary | Customer | Supplier | Alliance | Bank | Shareholder |
|---|---|---|---|---|---|---|---|---|
|
|
||||||||
|
|
||||||||
| Senha Trading (Shanghai) Co., Ltd. |
Network
History
In July 1947, Mr. Hideo Takami founded the Hamari Chemical Research Institute and began manufacturing saccharin.![]()
In December 1948, Hamari Chemical Co., Ltd. (Hamari Chemical Research Institute) was established, and production of bismuth products such as bismuth nitrate, acrylonitrile, and para-acetaminophen benzaldehyde began.![]()
In January 1966, President Hideo Takami presented the structure of L-DOPA and challenged industrial production.![]()
In 1980, a joint study on the anti-ulcer effects of the L-carnosine zinc complex was started with Professor Fujimura of Gifu University Medical School.![]()
Around 1990, the Hamari PFST Yonezawa Plant (formerly Yonezawa Hamari Pharmaceutical Industrial) was running a large cumulative deficit. To eliminate the deficit, Takami Jiro was transferred. He observed frequent machine breakdowns and halted production for monthly maintenance, but tools were often lost. The first step was to reduce inflated equipment-related costs.![]()
From 1992, a combined 5S and process improvement initiative began. Small groups called "circles" participated daily to build continuous improvement.![]()
In 1994, the generic name "Polaprezinc" was coined, and the new anti-ulcer drug "Promac" containing Polaprezinc as the active ingredient was launched by Zelia New Drug.![]()
In 2002, the 26th Great Invention Award Ishii Kōan Contribution Award and the 2000 Basic Coordination Engineering Research Society Technical Award were received.![]()
Since 2002, a target deadline has been set. The key to development is a hydrogen‑shift asymmetric hydrogenation of imine derivatives derived from substituted phenylacetone.![]()
Research using the Belokon complex was conducted from 2003 to 2004, but due to issues with its physical properties, selectivity, and patentability, the development was ultimately discontinued after about six months.![]()
From October 2010, the first study abroad program in the United States was realized by HAMARI researchers.![]()
In 2011, we were honored to receive the 61st Industrial Technology Award from the Osaka Institute of Technology Association.![]()
News
There is no news.